Imugene Doses First Patient In Phase-Two Study Of Cancer Vaccine

Imugene doses first patient in phase-two study of cancer vaccine

Proactive Investors

IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL

Imugene Limited

Imugene's Science Series featuring the Oncolytic Viraltherapy CHECKvacc

Imugene Limited

Imugene | First patients dosed in VAXINIA MAST combination study

Imugene Limited

Imugene (ASX: IMU) Presentation | NWR Virtual Healthcare Conference

NWR Communications

Imugene delighted as first cohort 3 patient dosed in CHECKvacc trial

Proactive Investors

Imugene Investor Webinar: MAST Study Update

Imugene Limited

Imugene @ AACR 2020: PD1-Vaxx (IMU-201) Phase 1 Briefing

Imugene Limited

Dr Marina Maglakelidze Presents HER-Vaxx Trial Data at ESMO 2019

Imugene Limited

Imugene doses first patient in Phase 1 onCARlytics IV infusion combination trial

Proactive Investors

Imugene thrilled with ethics approval for phase 2 HER-Vaxx trial

Proactive Investors

Imugene HER-Vaxx AACR 2021 Poster: Dr Rita Laeufle oral presentation

Imugene Limited

Imugene bringing effective new treatments and options to cancer patients

A clinical stage immuno-oncology company.

Imugene CEO hails clinical milestone for HER-Vaxx cancer immunotherapy

Proactive Investors

Imugene forges development path of immunotherapies and cancer-killing virus

Imugene finishes Phase 1a monotherapy dose escalation of PD1 Vaxx

Imugene Limited

Imugene talks dose escalation for CHECKvacc's City of Hope trial

Proactive Investors

Imugene (ASX:IMU) targeting gastric cancer

Finance News Network

Combination CAR T Oncolytic Virus Immunotherapy Kills Tumors

Imugene Limited